Drug Channels

SEPTEMBER 21, 2020

This important event convenes key stakeholders including manufacturers, specialty pharmacies, hubs, payers, PBMs, physicians and more to explore strategies for developing and integrating hub programs and other patient-centric services to ensure product access and optimal reimbursement. Arquette, R.Ph., REGISTER TODAY.

Specialty Pharmacies 52

Specialty Pharmacies Pharmacy Pharmaceuticals Production 52

Drug Channels

JULY 20, 2021

The 340B Drug Pricing Program continues to expand far more quickly than the overall pharmaceutical market—and some channels are benefiting more than others. As you will see below, mail and specialty pharmacies’ purchases of products that are eligible for 340B discounts have grown by an incredible 56% per year since 2017.

Specialty Pharmacies 52

Specialty Pharmacies Pharmacy Marketing Pharmaceuticals 52

Drug Channels

MARCH 15, 2022

Prescription Market (press release) We’re offering special discounted pricing if you order before March 28, 2022. Pharmacies and Pharmacy Benefit Managers , our 13th edition, provides a comprehensive, fact-based, and non-partisan tool for understanding the entire U.S. The 2022 Economic Report on U.S.

Pharmacy 98

Pharmacy Specialty Pharmacies Licensing Licensing 98

Drug Channels

NOVEMBER 8, 2020

Stuart Parker, Senior Director, Trade Relations, Mayne Pharma And more! Stuart Parker, Senior Director, Trade Relations, Mayne Pharma And more!

Specialty Pharmacies 52

Specialty Pharmacies Science Pharmacy Pharmaceuticals 52

Drug Channels

OCTOBER 19, 2020

Gain Critical Insight from Industry Trailblazers During a Time of Transformative Change – Speakers will include : Bill Roth, Founding Partner, Blue Fin Group Rob Osborne, Vice President Pharma Trade Relations, Express Scripts, Accredo, CuraScript SD Ray Tancredi, RPh, MBA, CSP, Divisional Vice President, Specialty Pharmacy Development & Brand Rx/Vaccine (..)

Specialty Pharmacies 52

Specialty Pharmacies Science Pharmacy Licensing 52

The Pharma Data

JANUARY 12, 2021

Akin to the NASA Deep Space Network, SYNERGY-AI OCTCC is a real time data and communication network between patients, sites, and pharmaceutical companies, with the Massive Bio AI-enabled engine orchestrating these stakeholders for successful operations. NEW YORK–( BUSINESS WIRE )– Massive Bio, Inc. , 75N91020C00016.

Clinical Trials 52

Clinical Trials Trials Clinical Research Pharmaceutical Companies 52

The Pharma Data

OCTOBER 27, 2020

The decrease in Adcirca revenues was driven by continued erosion of market share due to generic competition. Sales and marketing. Lung Biotechnology is the first public benefit corporation subsidiary of a public biotechnology or pharmaceutical company. Cost of product sales. .

FDA 40

FDA Production Licensing Licensing 40